REPORTS ON THERAPY Pharmacokinetics and Fibrin Specificity of Alteplase During Accelerated Infusions in Acute Myocardial Infarction

Phatmecokinetics and fibrin specificity of alteptase (recombinant thane-type plasminogen activator) were determined in IO patients with made, myorard td infarction undergoing as aorelers •^t alzsion regimen during the alteplaselaniatreplase potency study (TAPS). Fifteen milligrams of alteplase was a dministered as an intravenous halos injection, fdNowed by infisims of 50 mg over 30 min and 35 mg over a farther 60 min . Mean steady state plasma concentration; of alteplase during the initial 30 minwen 3.2 m 0 .84 μglnel, measured immaisadomleally, and 2.1 a 0.23 uglml, measured using a functional activity assay. These vatnts were 45% and 51 % higher, respectively, than those during the s?amlard infusion schedule (p < 0,01) . Iiowevec, the predominant plasma half-life determined by arodel fitting